FY2024 Earnings Forecast for PolyPid Issued By HC Wainwright

PolyPid Ltd. (NASDAQ:PYPDFree Report) – Equities researchers at HC Wainwright upped their FY2024 earnings per share estimates for PolyPid in a report released on Thursday, December 26th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($4.56) per share for the year, up from their previous estimate of ($4.83). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($4.39) per share. HC Wainwright also issued estimates for PolyPid’s Q4 2024 earnings at ($0.90) EPS, Q1 2025 earnings at ($0.74) EPS, Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.26) EPS and FY2025 earnings at ($1.79) EPS.

Separately, Craig Hallum started coverage on shares of PolyPid in a report on Monday, November 4th. They set a “buy” rating and a $10.00 target price on the stock.

Check Out Our Latest Report on PYPD

PolyPid Trading Up 1.4 %

Shares of PYPD stock opened at $2.89 on Monday. The stock has a market capitalization of $13.86 million, a P/E ratio of -0.37 and a beta of 1.33. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.17. PolyPid has a fifty-two week low of $2.37 and a fifty-two week high of $9.20. The stock has a 50-day simple moving average of $3.24 and a 200 day simple moving average of $3.51.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in PolyPid stock. Stonepine Capital Management LLC purchased a new position in shares of PolyPid Ltd. (NASDAQ:PYPDFree Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned about 2.89% of PolyPid as of its most recent SEC filing. Hedge funds and other institutional investors own 26.47% of the company’s stock.

About PolyPid

(Get Free Report)

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.

See Also

Earnings History and Estimates for PolyPid (NASDAQ:PYPD)

Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.